Canada markets closed

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.53-0.24 (-0.90%)
At close: 04:00PM EST
26.53 0.00 (0.00%)
After hours: 04:31PM EST

Myriad Genetics, Inc.

320 Wakara Way
Salt Lake City, UT 84108
United States
801 584 3600

IndustryDiagnostics & Research
Full Time Employees2,700

Key Executives

NameTitlePayExercisedYear Born
Mr. Paul J. DiazCEO, Pres & Director1.99MN/A1962
Mr. R. Bryan RiggsbeeExec. VP, CFO & Treasurer741.84kN/A1971
Ms. Nicole LambertChief Operating Officer507.51kN/A1974
Mr. Mark S. VerrattiPres of Myriad Neuroscience & Autoimmune560.7kN/A1968
Dr. Kevin Richard HaasChief Technology OfficerN/AN/A1986
Dale Muzzey Ph.D.Sr. VP of R&D & Interim Chief Scientific OfficerN/AN/AN/A
Mr. Scott GleasonSr. VP of Investor RelationsN/AN/AN/A
Mr. Nathan SmithSr. VP of Investor Relations & TreasuryN/AN/AN/A
Dr. Clivetty MartinezChief Compliance OfficerN/AN/AN/A
Ms. Pamela WongChief Legal OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Corporate Governance

Myriad Genetics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 5. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 6; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.